Variation in cannabis potency and prices in a newly legal market: evidence from 30 million cannabis sales in Washington state

AIMS To (1) assess trends and variation in the market share of product types and potency sold in a legal cannabis retail market and (2) estimate how potency and purchase quantity influence price variation for cannabis flower. DESIGN Secondary analysis of publicly available data from Washington State's cannabis traceability system spanning 7 July 2014 to 30 September 2016. Descriptive statistics and linear regressions assessed variation and trends in cannabis product variety and potency. Hedonic regressions estimated how purchase quantity and potency influence cannabis flower price variation. SETTING Washington State, USA. PARTICIPANTS (1) A total of 44 482 176 million cannabis purchases, including (2) 31 052 123 cannabis flower purchases after trimming price and quantity outliers. MEASUREMENTS Primary outcome measures were (1) monthly expenditures on cannabis, total delta-9-tetrahydrocannabinol (THC) concentration and cannabidiol (CBD) concentration by product type and (2) excise tax-inclusive price per gram of cannabis flower. Key covariates for the hedonic price regressions included quantity purchased, THC and CBD. FINDINGS Traditional cannabis flowers still account for the majority of spending (66.6%), but the market share of extracts for inhalation increased by 145.8% between October 2014 and September 2016, now comprising 21.2% of sales. The average THC-level for cannabis extracts is more than triple that for cannabis flowers (68.7% compared to 20.6%). For flower products, there is a statistically significant relationship between price per gram and both THC [coefficient = 0.012; 95% confidence interval (CI) = 0.011-0.013] and CBD (coefficient = 0.017; CI = 0.015-0.019). The estimated discount elasticity is -0.06 (CI = -0.07 to -0.05). CONCLUSIONS In the state of Washington, USA, the legal cannabis market is currently dominated by high-THC cannabis flower, and features growing expenditures on extracts. For cannabis flower, both THC and CBD are associated with higher per-gram prices, and there are small but significant quantity discounts.

[1]  J. Caulkins,et al.  What America's Users Spend on Illegal Drugs, 2006–2016 , 2019 .

[2]  R. Murray,et al.  Can we make cannabis safer? , 2017, The lancet. Psychiatry.

[3]  R. Pacula,et al.  Medical Marijuana and Marijuana Legalization. , 2017, Annual review of clinical psychology.

[4]  S. Garrett,et al.  Beyond joints and brownies: Marijuana concentrates in the legal landscape of WA State. , 2017, The International journal on drug policy.

[5]  J. Cusack.  The war on drugs is lost... so what do we do now , 2016 .

[6]  W. Hall,et al.  Why it is probably too soon to assess the public health effects of legalisation of recreational cannabis use in the USA. , 2016, The lancet. Psychiatry.

[7]  R. Niesink,et al.  Limitations to the Dutch cannabis toleration policy: Assumptions underlying the reclassification of cannabis above 15% THC. , 2016, The International journal on drug policy.

[8]  L. DeLisi,et al.  Effects of Cannabis Use on Human Behavior, Including Cognition, Motivation, and Psychosis: A Review. , 2016, JAMA psychiatry.

[9]  F. Wolff,et al.  Price elasticity of demand for cannabis: does potency matter? , 2016 .

[10]  Dustin C. Lee,et al.  Online survey characterizing vaporizer use among cannabis users. , 2016, Drug and alcohol dependence.

[11]  C. Kaplan,et al.  Understanding dabs: contamination concerns of cannabis concentrates and cannabinoid transfer during the act of dabbing. , 2015, The Journal of toxicological sciences.

[12]  R. MacCoun.  Commentary on Niesink et al. (2015): Interpreting trends in tetrahydrocannabinol potency--three stories, one of which may be true. , 2015, Addiction.

[13]  R. Niesink,et al.  Potency trends of Δ9-tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands: 2005-15. , 2015, Addiction.

[14]  Melissa J. Krauss,et al.  Displays of dabbing marijuana extracts on YouTube. , 2015, Drug and alcohol dependence.

[15]  Francois R. Lamy,et al.  "Time for dabs": Analyzing Twitter data on marijuana concentrates across the U.S. , 2015, Drug and alcohol dependence.

[16]  D. Camenga,et al.  Pediatrics Digest , 2015, Pediatrics.

[17]  A. Winstock,et al.  Examining the profile of high-potency cannabis and its association with severity of cannabis dependence , 2015, Psychological Medicine.

[18]  Bryan Lee Miller,et al.  Assessing the Dangers of “Dabbing”: Mere Marijuana or Harmful New Trend? , 2015, Pediatrics.

[19]  K. Hill.  Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review. , 2015, JAMA.

[20]  Penny F Whiting,et al.  Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. , 2015, JAMA.

[21]  Sheigla Murphy,et al.  Baby Boomers and Cannabis Delivery Systems , 2015 .

[22]  L. Degenhardt,et al.  High potency cannabis , 2015, BMJ : British Medical Journal.

[23]  Paola Dazzan,et al.  Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. , 2015, The lancet. Psychiatry.

[24]  J. Etter.  Electronic Cigarettes and Cannabis: An Exploratory Study , 2015, European Addiction Research.

[25]  C. Morgan,et al.  Just say 'know': how do cannabinoid concentrations influence users' estimates of cannabis potency and the amount they roll in joints? , 2014, Addiction.

[26]  Mitch Earleywine,et al.  A new method of cannabis ingestion: the dangers of dabs? , 2014, Addictive behaviors.

[27]  R. de Graaf,et al.  Cross-sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological study. , 2014, Addiction.

[28]  Nora D Volkow,et al.  Adverse health effects of marijuana use. , 2014, The New England journal of medicine.

[29]  E. Maa,et al.  The case for medical marijuana in epilepsy , 2014, Epilepsia.

[30]  J. Malouff,et al.  Experiences of Marijuana-Vaporizer Users , 2014, Substance abuse.

[31]  Anthony Gamst,et al.  The Use and Perception of Electronic Cigarettes and Snus among the U.S. Population , 2013, PloS one.

[32]  J. Caulkins,et al.  Design considerations for legalizing cannabis: lessons inspired by analysis of California's Proposition 19. , 2012, Addiction.

[33]  Mahmoud A. ElSohly,et al.  Potency Trends of Δ9‐THC and Other Cannabinoids in Confiscated Cannabis Preparations from 1993 to 2008 * , 2010, Journal of forensic sciences.

[34]  J. Caulkins,et al.  Economic analysis of drug transaction ‘cycles’ described by incarcerated UK drug dealers , 2009 .

[35]  Matt Field,et al.  The effects of price and perceived quality on the behavioural economics of alcohol, amphetamine, cannabis, cocaine, and ecstasy purchases. , 2007, Drug and alcohol dependence.

[36]  Kenneth W. Clements,et al.  Pricing and Packaging: The Case of Marijuana , 2006 .

[37]  J. Caulkins,et al.  Marijuana Markets: Inferences from Reports by the Household Population , 2006 .

[38]  Neil Smith.  High potency cannabis: the forgotten variable. , 2005, Addiction.

[39]  Patrick Paul Walsh,et al.  Modelling Price Dispersion as an Outcome of Competition in the Irish Grocery Market , 2003 .

[40]  E. Duflo,et al.  How Much Should We Trust Differences-in-Differences Estimates? , 2001 .

[41]  M. Thornton.  The Potency of Illegal Drugs , 1998 .

[42]  Rema Padman,et al.  Quantity Discounts and Quality Premia for Illicit Drugs , 1993 .

[43]  P. Gruenewald,et al.  Alcohol beverage price spectra: opportunities for substitution. , 1993, Alcoholism, clinical and experimental research.

[44]  David A. Wise,et al.  Price Differences in almost Competitive Markets , 1979 .

[45]  S. Rosen.  Hedonic Prices and Implicit Markets: Product Differentiation in Pure Competition , 1974, Journal of Political Economy.

[46]  B. Kilmer.  Recreational Cannabis - Minimizing the Health Risks from Legalization. , 2017, New England Journal of Medicine.

[47]  W. Hall.  What has research over the past two decades revealed about the adverse health effects of recreational cannabis use? , 2015, Addiction.

[48]  Simone Pettigrew,et al.  Issues in the implementation and evolution of the commercial recreational cannabis market in Colorado. , 2015, The International journal on drug policy.

[49]  Eleanor Kennedy.  High potency cannabis and the risk of psychosis , 2015 .

[50]  Eric L. Sevigny,et al.  Is today's marijuana more potent simply because it's fresher? , 2013, Drug testing and analysis.

[51]  M. Field,et al.  The effects of perceived quality on the behavioural economics of alcohol, amphetamine, cannabis, cocaine, and ecstasy purchases. , 2008, Drug and alcohol dependence.

[52]  J. Ramaekers,et al.  High-Potency Marijuana Impairs Executive Function and Inhibitory Motor Control , 2006, Neuropsychopharmacology.

[53]  P. Reuter,et al.  Illegal “ lemons ” : price dispersion in cocaine and heroin markets * , 2006 .

[54]  Carnis Laurent.  The Economics Of Prohibition , 1999 .